Gut Bacteria Could Predict Parkinson’s Disease Years Before Symptoms Appear, Study Finds

Specific bacteria in the gut microbiome may serve as early warning signs for Parkinson’s disease, potentially allowing for detection years before traditional symptoms emerge, according to groundbreaking new research.

In an observational study led by University College London (UCL), researchers analyzed the gut microbes of 271 patients diagnosed with Parkinson’s disease in the United Kingdom. The study, published in Nature Medicine, also included 43 carriers of the GBA1 gene variant—individuals with nearly 30 times higher risk of developing Parkinson’s but who were not yet symptomatic—alongside a control group of 150 healthy participants without the gene.

Analysis of fecal samples revealed that more than 25% of gut microbes—bacteria and other microorganisms in the digestive tract—appeared in significantly different amounts in Parkinson’s patients compared to healthy individuals. Perhaps most significantly, asymptomatic carriers of the Parkinson’s-linked gene displayed microbial patterns resembling an “intermediate” stage of the disease, suggesting these changes may precede the onset of clinical symptoms.

“Parkinson’s disease is a major cause of disability worldwide, and the fastest growing neurodegenerative disease in terms of prevalence and mortality,” explained lead author Professor Anthony Schapira of the UCL Queen Square Institute of Neurology. “There is an urgent need to develop treatments that can stop or slow the disease’s progression.”

The findings gained additional credibility when researchers detected similar patterns in over 1,400 participants across the UK, Korea, and Turkey, indicating that these microbial signatures remain consistent across different cultures and dietary patterns.

Diet appears to play an important role in these bacterial configurations. Study participants who reported consuming a more diverse and balanced diet were less likely to exhibit microbiome patterns associated with higher Parkinson’s risk, potentially pointing toward dietary interventions as a preventative approach.

Dr. Earnest Lee Murray, a board-certified neurologist at Jackson-Madison County General Hospital who was not involved in the research, noted that the findings align with clinical observations of Parkinson’s patients experiencing significant gut abnormalities.

“Patients with Parkinson’s are known to have severe constipation, which can occur several years before tremors and other symptoms,” Murray told Fox News Digital. “There has long been a theory about the gut-brain axis and whether the pathology for Parkinson’s starts in the gut decades before stereotypical features are noted.”

The study provides compelling support for the gut-brain axis theory, potentially opening new avenues for early intervention strategies. Murray emphasized the importance of such research, noting that “with an aging population that is living longer, the prevalence of Parkinson’s is increasing significantly.”

Dr. Aaron Ellenbogen, medical director of the Parkinson’s Disease & Movement Disorders Center at the Michigan Institute for Neurological Disorders, offered additional perspective on how these findings relate to different Parkinson’s presentations.

“In general, people with GBA mutations tend to have Parkinson’s symptoms evolve in a way that is more consistent with a gut-first presentation,” explained Ellenbogen. He contrasted this with other patients who may experience different early symptoms, such as loss of smell, before developing motor symptoms. “These people may actually have a form of Parkinson’s that starts in the brain,” he added.

Despite its promising implications, the research has limitations. As an observational study, it cannot establish that microbiome changes directly cause Parkinson’s disease. The researchers acknowledged that not everyone with at-risk microbiome profiles will develop the condition, as various genetic and environmental factors likely play roles in disease progression.

Additionally, microbiome differences across diverse populations could influence results, necessitating further research before clinical applications can be developed.

“To enable both the research and eventual use of such treatments, we need to develop the means for very early detection of people who will, or likely will, go on to develop the disease,” Schapira stated.

The study, funded by the Michael J. Fox Foundation for Parkinson’s Research and the UK Medical Research Council, represents a significant step toward potential early intervention strategies for a disease that currently has no cure and affects millions worldwide.